FDA Drug Shortage Database
Methotrexate (Rasuvo) shortage
The FDA Drug Shortage Database lists 7 of 14 methotrexate presentations as limited or unavailable (updated October 6, 2026); the first entry was posted on March 13, 2023. 7 more presentations are on the list as available.
- Generic listed
- In shortage
- Boxed warning
Check it at the source: the FDA Drug Shortage Database.
Which strengths are short?
| Strength | Limited or unavailable now | Listed now, available | Resolved or discontinued |
|---|---|---|---|
| 1g injection | 1 | 1 | 0 |
| 1g/40ml injection | 0 | 3 | 0 |
| 25mg/1ml injection | 6 | 1 | 0 |
| 50mg/2ml injection | 0 | 2 | 0 |
Which presentations are listed?
Limited or unavailable now (7)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01) | Teva Pharmaceuticals USA, Inc. | Current posted March 13, 2023, updated October 1, 2026 | Limited Availability; Other |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01) | Teva Pharmaceuticals USA, Inc. | Current posted March 13, 2023, updated October 1, 2026 | Limited Availability; Other |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01) | Teva Pharmaceuticals USA, Inc. | Current posted March 13, 2023, updated October 1, 2026 | Limited Availability; Other |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30) | Accord Healthcare Inc. | Current posted March 13, 2023, updated October 3, 2026 | Unavailable; Other |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35) | Accord Healthcare Inc. | Current posted March 13, 2023, updated October 3, 2026 | Unavailable; Other |
| Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01) | Hikma Pharmaceuticals USA, Inc. | Current posted March 13, 2023, updated September 18, 2026 | Unavailable; Demand increase for the drug |
| Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10) | Hikma Pharmaceuticals USA, Inc. | Current posted March 13, 2023, updated September 18, 2026 | Unavailable; Demand increase for the drug |
Listed now, available (7)
| Presentation | Company | Status and dates | Availability and reason given |
|---|---|---|---|
| Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50) | Fresenius Kabi USA, LLC | Current posted March 13, 2023, updated October 6, 2026 | Available |
| Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40) | Hospira, Inc., a Pfizer Company | Current posted March 13, 2023, updated September 22, 2026 | Available |
| Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25) | Hospira, Inc., a Pfizer Company | Current posted March 13, 2023, updated September 22, 2026 | Available |
| Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41) | Hospira, Inc., a Pfizer Company | Current posted March 13, 2023, updated September 22, 2026 | Available |
| Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10) | Fresenius Kabi USA, LLC | Current posted March 13, 2023, updated October 6, 2026 | Available |
| Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10) | Hospira, Inc., a Pfizer Company | Current posted March 13, 2023, updated September 22, 2026 | Available |
| Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38) | Hospira, Inc., a Pfizer Company | Current posted March 13, 2023, updated September 22, 2026 | Available |
Source: FDA Drug Shortage Database via openFDA, read October 8, 2026
Are medicines for the same conditions short too?
Medicines whose labels share an indication with this one, and their own shortage status; listed as records, not substitutes.
| Medicine | Shared indication | Shortage | Generic labelers | Pharmacy cost |
|---|---|---|---|---|
| Indomethacin | Rheumatoid arthritis | No current entry | 31 labelers | $0.210 per capsule 75 mg capsule |
| Hydroxychloroquine | Rheumatoid arthritis | A presentation being discontinued | 28 labelers | $0.149 per tablet 200 mg tablet |
| Tofacitinib | Rheumatoid arthritis | No current entry | 24 labelers | $0.573 per tablet 5 mg tablet |
| Leflunomide | Rheumatoid arthritis | A presentation being discontinued | 16 labelers | $0.324 per tablet 10 mg tablet |
| Penicillamine | Rheumatoid arthritis | No current entry | 9 labelers | n/a |
| Baricitinib | Rheumatoid arthritis | No current entry | none listed | $92.54 per tablet 2 mg tablet |
| Flurbiprofen | Rheumatoid arthritis | No current entry | 7 labelers | $9.83 per mL 0.03% eye drop |
| Upadacitinib | Rheumatoid arthritis | No current entry | none listed | $229.31 per tablet 15 mg tablet |
| Auranofin | Rheumatoid arthritis | No current entry | none listed | $24.85 per capsule 3 mg capsule |
Source: FDA drug labels, FDA Drug Shortage Database, NDC Directory, CMS NADAC of October 7, 2026 (FDA files October 8, 2026)
What next?
- Every shortage now
- medicines by presentations in shortage